ARTICLE | Editor’s Commentary
Lilly quiet on safety as Zepbound beats Wegovy in head-to-head trial
By Stephen Hansen, Director of Biopharma Intelligence
December 5, 2024 12:40 AM UTC
It’s no surprise that Lilly’s Zepbound produced more weight loss than Novo’s Wegovy in a head-to-head trial. Yet-to-be disclosed tolerability data for the drug will be more meaningful in increasing Lilly’s share of the obesity market.
The efficacy result Eli Lilly and Co. (NYSE:LLY) announced on Wednesday was expected, confirming what was clearly evident in the companies’ independently conducted Phase III trials. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654386/tolerability-data-will-matter-more-than-efficacy-in-zepbound-vs-wegovy-a-perspective